- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05754684
Quadruple Immunotherapy for Neuroblastoma
Quadruple Immunotherapy for Paediatric Patients With Relapsed or Refractory Neuroblastoma
Study Overview
Status
Conditions
Detailed Description
Included patients will receive intravenous infusion of donor NK cells on day 0, and anti-GD2 antibody (dinutuximab) on day -6 to day -2. IL-2 will be given subcutaneously on day -1, day +1, day +3, day +5, day +7, and day +9. Subcutaneous injection of GM-CSF will be started on day 0, given daily till neutrophil count >1000/mm3. Spironolactone will be started orally on day -1, given three times daily till cessation of GM-CSF.
Alternative anti-GD2 antibody (Naxitamab) can be used instead of dinutuximab, to be given on day -5, day -3, day +1 and day +3.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Daniel Cheuk
- Phone Number: 852-35136049
- Email: cheukkld@gmail.com
Study Locations
-
-
-
Hong Kong, Hong Kong
- Recruiting
- Hong Kong Children's Hospital
-
Contact:
- Daniel Cheuk
- Phone Number: 851-35136049
- Email: cheukkld@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- relapsed or refractory neuroblastoma
- Adequate organ function: creatinine clearance ≥40 ml/min/1.73m2, total bilirubin ≤3 times upper limit of normal and ALT ≤500 IU/L, left ventricular shortening fraction ≥25%, and oxygen saturation ≥92% in room air
- Karnofsky or Lansky performance status score ≥50
- Has an appropriate HLA-haploidentical NK-cell donor available
Exclusion Criteria:
- Pregnant or lactating woman
- HIV infection
- Patients for whom conventional treatment is deemed more appropriate
- Patients who are unlikely to benefit, e.g., terminal malignancy with life expectancy <1 month
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
Quadruple immunotherapy
|
Natural killer cells isolated from HLA-haploidentical relative donor
Other Names:
Dinutuximab beta iv for 5 days
Other Names:
Interleukin-2 sc alternate day for 6 doses
Other Names:
Granulocyte-macrophage colony-stimulating factor sc daily till ANC >2,000/mm3
Other Names:
Spironolactone po three time daily
Other Names:
Naxitamab iv for 4 days (as alternative for dinutuximab)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients who have objective response in the tumor
Time Frame: 1-2 months
|
Objective response = complete response + partial response + minor response + stable disease
|
1-2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival at 1 year
Time Frame: up to 1 year
|
From the date of treatment start until the date of death from any cause, assessed up to 1 year
|
up to 1 year
|
Progression-free survival
Time Frame: up to 1 year
|
From date of treatment start until the date of first documented progression or the date of death from any cause, whichever comes first, assessed up to 1 year
|
up to 1 year
|
Proportion of patients who have tumor relapse
Time Frame: up to 1 year
|
relapse = reappearance of tumor after complete response
|
up to 1 year
|
Number of patients who experience adverse events
Time Frame: up to 1 month
|
Adverse events are graded according to Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events version 5 (CTCAEv5)
|
up to 1 month
|
Percentage of donor NK cells
Time Frame: up to 1 year
|
Percentage of donor natural killer cells in the recipient's blood will be evaluated weekly from the date of NK cell infusion for 4 weeks, then every 2 weeks till donor NK cells are undetectable
|
up to 1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Daniel Cheuk, Hong Kong Children's Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroectodermal Tumors, Primitive
- Neuroectodermal Tumors, Primitive, Peripheral
- Neuroblastoma
- Physiological Effects of Drugs
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Antiviral Agents
- Anti-HIV Agents
- Anti-Retroviral Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Antineoplastic Agents
- Immunologic Factors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Natriuretic Agents
- Diuretics
- Hormone Antagonists
- Mineralocorticoid Receptor Antagonists
- Diuretics, Potassium Sparing
- Aldesleukin
- Spironolactone
- Sargramostim
- Dinutuximab
- Interleukin-2
- Molgramostim
Other Study ID Numbers
- HKCH-REC-2021-007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuroblastoma Recurrent
-
National Cancer Institute (NCI)CompletedRecurrent Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 NeuroblastomaUnited States, Canada
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Neuroblastoma | Disseminated Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S NeuroblastomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Neuroblastoma | Refractory NeuroblastomaUnited States, Canada
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingRecurrent Neuroblastoma | Stage 4S Neuroblastoma | Stage 2A Neuroblastoma | Stage 2B Neuroblastoma | Stage 3 Neuroblastoma | Stage 4 NeuroblastomaUnited States, Canada, Australia, New Zealand
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 NeuroblastomaUnited States, Canada, Australia, New Zealand, Puerto Rico
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 NeuroblastomaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4 NeuroblastomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Neuroblastoma | Disseminated Neuroblastoma | Localized Unresectable Neuroblastoma | Regional NeuroblastomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Neuroblastoma | Disseminated Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Stage 4S NeuroblastomaUnited States
-
National Cancer Institute (NCI)SuspendedRecurrent Neuroblastoma | Recurrent Osteosarcoma | Refractory Neuroblastoma | High Risk Neuroblastoma | Resectable OsteosarcomaUnited States, Canada
Clinical Trials on Natural killer cell
-
Wenxiang WangShanghai Houchao Biotechnology Co., LtdUnknownNon-small Cell Lung CancerChina
-
Minghui ZhangShanghai Public Health Clinical Center; First Hospital of Tsinghua UniversityRecruitingHepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Non-small Cell Lung CancerChina
-
Yonsei UniversityCompletedAdvanced Biliary Tract CancerKorea, Republic of
-
Asan Medical CenterKorea Research Institute of Bioscience & BiotechnologyCompletedAcute Lymphoblastic Leukemia | Acute Myelogenous LeukemiaKorea, Republic of
-
Asan Medical CenterKorea Research Institute of Bioscience & BiotechnologyCompletedLymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Brain and Central Nervous System Tumors | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative NeoplasmsKorea, Republic of
-
Seoul National University HospitalCompleted
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompleted
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedPancreatic CancerChina
-
Envita Medical Center, Inc.SuspendedGlioma | Breast Cancer | Pancreatic Cancer | Prostate Cancer | Colon Cancer | Hepatocellular Cancer | Squamous Cell Lung CancerUnited States
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedNon-small Cell Lung Cancer MetastaticChina